gnbt - momento da verdade
nk667 Escreveu:Saiu alguma noticia, ou foi algo tecnico? ou algem sabe algo que nos nao sabemos
Vamos ver se è desta que vai levantar voo
Bons negocios
Repara no meu gráfico de 3ºfeira que publiquei, ela já tinha dado ali o sinal técnico. Deixo-te o gráfico do fecho de ontem com o breakout e o comentário está no meu blog em inglês
- Anexos
-
- sc.png (23.23 KiB) Visualizado 6683 vezes
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
Já está...... agora era só um fecho acima desta área para o volume confirmar o breakout......
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
O Breakout está iminente, olhando para o volume de hoje..... a possibilidade rondará os 80%.
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
Eu ontem fiz uma análise á GNBT no meu blog e esqueci-me de passar por aqui para deixar o gráfico. Aqui fica o gráfico de ontem que mais ou menos serve para hoje....
- Anexos
-
- sc.png (39.85 KiB) Visualizado 6894 vezes
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
Re: Ò Pedrito 200
Zezezinho Escreveu:AC Investor Blog Escreveu:Por acaso também faz parte de alguns porfólios meus, com entrada junto á zona dos 0.35.
Sim Sim...
AC Investor Blog Escreveu:Eu estou longo na GNBT ( desde os 0.385 ), não propriamente numa base técnica , mas sim numa possibilidade de sucesso dos produtos ( AE37 ). Fica aqui os ultimos rumores.AC Investor Blog Escreveu:Eu acabei de rapar um lote a 0.435 para acumular as minhas que detenho já á mais de 2 semanas. Compras estranhas de mais de 100 mil fizeram o titulo disprar em poucos segundos. Alguém sabe algo que o mercado só saberá hoje á noite ou amanhã antes do mercado abrir.
Sou um trader
Tão depressa entro como saio...
Repara na palavra , porfólios
significa que não é uma carteira sóAC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
Re: Ò Pedrito 200
AC Investor Blog Escreveu:Por acaso também faz parte de alguns porfólios meus, com entrada junto á zona dos 0.35.
Sim Sim...
AC Investor Blog Escreveu:Eu estou longo na GNBT ( desde os 0.385 ), não propriamente numa base técnica , mas sim numa possibilidade de sucesso dos produtos ( AE37 ). Fica aqui os ultimos rumores.
AC Investor Blog Escreveu:Eu acabei de rapar um lote a 0.435 para acumular as minhas que detenho já á mais de 2 semanas. Compras estranhas de mais de 100 mil fizeram o titulo disprar em poucos segundos. Alguém sabe algo que o mercado só saberá hoje á noite ou amanhã antes do mercado abrir.
-
- Mensagens: 480
- Registado: 30/6/2010 0:10
- Localização: 11
Re: Ò Pedrito 200
Iniciado Escreveu:Ò Pedrito 200 não é meu habito colocar este tipo de posts ,....mas estás enterradito na gnbt....ou é impressão minha?
Por acaso também faz parte de alguns porfólios meus, com entrada junto á zona dos 0.35. É um titulo com algum risco anerente, mas o risco/proveito é aliciante. Caso o medicamento seja aprovado temos aqui uma nova DNDN.....
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
Re: Institutional Holdings
pedro200 Escreveu:Novos fundos a entrar na Generex:
RENAISSANCE TECHNOLO 6/30/2010 994,108 New
BARCLAYS PLC 6/30/2010 541,317 New
DEUTSCHE BANK AG\ 6/30/2010 452,697 New
informação ver:
http://www.nasdaq.com/asp/holdings.asp? ... titutional
Será que ainda estão em carteira? ou já foram vendidas a 0,40USD?
- Mensagens: 1072
- Registado: 29/11/2007 4:08
- Localização: Santa Maria da Feira
Ò Pedrito 200
Ò Pedrito 200 não é meu habito colocar este tipo de posts ,....mas estás enterradito na gnbt....ou é impressão minha?
-
- Mensagens: 580
- Registado: 22/12/2005 15:42
- Localização: Ourèm
Institutional Holdings
Novos fundos a entrar na Generex:
RENAISSANCE TECHNOLO 6/30/2010 994,108 New
BARCLAYS PLC 6/30/2010 541,317 New
DEUTSCHE BANK AG\ 6/30/2010 452,697 New
informação ver:
http://www.nasdaq.com/asp/holdings.asp? ... titutional
RENAISSANCE TECHNOLO 6/30/2010 994,108 New
BARCLAYS PLC 6/30/2010 541,317 New
DEUTSCHE BANK AG\ 6/30/2010 452,697 New
informação ver:
http://www.nasdaq.com/asp/holdings.asp? ... titutional
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Los Angeles Times , 16 de Agosto de 2010:
http://articles.latimes.com/2010/aug/16 ... y-20100816
http://www1.generex.com/fckuploads/file/latimes.pdf
....
http://articles.latimes.com/2010/aug/16 ... y-20100816
http://www1.generex.com/fckuploads/file/latimes.pdf
....
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
AC Investor Blog Escreveu:O tónico começa a virar de tom : http://seekingalpha.com/article/220670- ... urce=yahoo
:)
O Oral-lyn e o AE37 são os 2 produtos de referência da Generex....
Será que as Grandes Farmacêuticas vão deixar que a Generex chegue sozinha ao mercado.....
A Pfizer tem gasto biliões em produtos semelhantes e falhou.... A MNKD tem a decisão da FDA adiada para Dezembro.. só que o produto deles apresenta contra-indicações....
ah! e parece que os fundos andam a encher a carteira com acções da generex...
Só a Renaissance comprou 1 milhão de acções...- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
O tónico começa a virar de tom : http://seekingalpha.com/article/220670- ... urce=yahoo
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
6 de Agosto de 2010:
PR Generex
Dear Stockholder:
You are cordially invited to attend a special meeting of stockholders of Generex Biotechnology Corporation ("Generex") that will be held on Friday, September 17, 2010, at 10:00 a.m. (local time), at the Meeting Rooms, Westin Harbour Castle Hotel, 1 Harbour Square, Toronto, Ontario Canada M5J 1A6, for the following purposes, as set forth in the accompanying Proxy Statement:
1. To approve an amendment to our Restated Certificate of Incorporation (i) to effect a reverse stock split of our common stock, at an exchange ratio of not less than 1-for-2 and not more than 1-for-10 at any time prior to September 16, 2011 (the implementation of the reverse stock split, ratio and timing of which will be subject to the discretion of the Board of Directors), and (ii) following the reverse stock split, if implemented, to reduce the number of authorized shares of common stock from 750,000,000 to 500,000,000 unless the Board of Directors utilizes a ratio of not more than 1-for-2, in which case, the number of authorized shares of common stock will be maintained at 750,000,000;
2. To approve the adjournment of the Generex special meeting, if necessary, to solicit additional proxies for the foregoing proposal; and
3. To conduct any other business as may properly come before the Generex special meeting or any adjournment or postponement thereof.
The Board of Directors has established the close of business on August 17, 2010, as the record date for the determination of stockholders entitled to receive notice of, and to vote at, the special meeting and any adjournment or postponement thereof. This Notice and the Proxy Statement and the attached proxy card are being mailed to stockholders on or about August [ ], 2010.
PR Generex
Dear Stockholder:
You are cordially invited to attend a special meeting of stockholders of Generex Biotechnology Corporation ("Generex") that will be held on Friday, September 17, 2010, at 10:00 a.m. (local time), at the Meeting Rooms, Westin Harbour Castle Hotel, 1 Harbour Square, Toronto, Ontario Canada M5J 1A6, for the following purposes, as set forth in the accompanying Proxy Statement:
1. To approve an amendment to our Restated Certificate of Incorporation (i) to effect a reverse stock split of our common stock, at an exchange ratio of not less than 1-for-2 and not more than 1-for-10 at any time prior to September 16, 2011 (the implementation of the reverse stock split, ratio and timing of which will be subject to the discretion of the Board of Directors), and (ii) following the reverse stock split, if implemented, to reduce the number of authorized shares of common stock from 750,000,000 to 500,000,000 unless the Board of Directors utilizes a ratio of not more than 1-for-2, in which case, the number of authorized shares of common stock will be maintained at 750,000,000;
2. To approve the adjournment of the Generex special meeting, if necessary, to solicit additional proxies for the foregoing proposal; and
3. To conduct any other business as may properly come before the Generex special meeting or any adjournment or postponement thereof.
The Board of Directors has established the close of business on August 17, 2010, as the record date for the determination of stockholders entitled to receive notice of, and to vote at, the special meeting and any adjournment or postponement thereof. This Notice and the Proxy Statement and the attached proxy card are being mailed to stockholders on or about August [ ], 2010.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Boa Noite!
Alguém tem acesso a este site?
www.mffais.com
conseguem colocar neste post as posições dos fundos na gnbt?
Obrigado
Alguém tem acesso a este site?
www.mffais.com
conseguem colocar neste post as posições dos fundos na gnbt?
Obrigado
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
pedro200 Escreveu:Acabou de Sair....
.... Dr. Craig Eagle .....
Generex Oncology Names Dr. Craig Eagle to Its Scientific Advisory Board to Assist With Its Proprietary Cancer Vaccines Program
WORCESTER, Mass., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today that it has named Craig Eagle, M.D. to its scientific advisory board. Dr. Eagle brings a wealth of oncology experience to help the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), dba "Generex Oncology," further its synthetic cancer and influenza vaccine development efforts. Dr. Eagle currently serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at Pfizer Inc.
Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney. He was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his training he performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets. He joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management.
In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the world wide lead for development of celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for irinotecan and dalteparin. In 2007, he became head of the oncology therapeutic area global medical group for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.
"We are very pleased to add Dr. Eagle to our team of scientific advisors," stated Anna Gluskin, the Company's President & Chief Executive Officer. "His wealth of experience in oncology and drug development will be invaluable as we work to advance our vaccine technologies at Antigen Expres
s. Additionally, his hands-on experience in strategic alliances and partnerships will provide us with additional guidance as we seek to commercialize these platforms in the future."
Commenting on his decision to join the scientific advisory board of Generex, Dr. Eagle stated: "I am very excited to be a part of the important advancements in cancer vaccine technologies being made at Generex Oncology. I look forward to advising the Company in its future oncology development efforts and helping Generex to navigate this important platform through its remaining trials and on to eventual commercialization."
A Generex está a formar um verdadeiro "Dream Team" para o seu Scientific Advisory Board!
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Acabou de Sair....
.... Dr. Craig Eagle .....
Generex Oncology Names Dr. Craig Eagle to Its Scientific Advisory Board to Assist With Its Proprietary Cancer Vaccines Program
WORCESTER, Mass., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today that it has named Craig Eagle, M.D. to its scientific advisory board. Dr. Eagle brings a wealth of oncology experience to help the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), dba "Generex Oncology," further its synthetic cancer and influenza vaccine development efforts. Dr. Eagle currently serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at Pfizer Inc.
Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney. He was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his training he performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets. He joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management.
In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the world wide lead for development of celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for irinotecan and dalteparin. In 2007, he became head of the oncology therapeutic area global medical group for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.
"We are very pleased to add Dr. Eagle to our team of scientific advisors," stated Anna Gluskin, the Company's President & Chief Executive Officer. "His wealth of experience in oncology and drug development will be invaluable as we work to advance our vaccine technologies at Antigen Express. Additionally, his hands-on experience in strategic alliances and partnerships will provide us with additional guidance as we seek to commercialize these platforms in the future."
Commenting on his decision to join the scientific advisory board of Generex, Dr. Eagle stated: "I am very excited to be a part of the important advancements in cancer vaccine technologies being made at Generex Oncology. I look forward to advising the Company in its future oncology development efforts and helping Generex to navigate this important platform through its remaining trials and on to eventual commercialization."
.... Dr. Craig Eagle .....
Generex Oncology Names Dr. Craig Eagle to Its Scientific Advisory Board to Assist With Its Proprietary Cancer Vaccines Program
WORCESTER, Mass., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today that it has named Craig Eagle, M.D. to its scientific advisory board. Dr. Eagle brings a wealth of oncology experience to help the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), dba "Generex Oncology," further its synthetic cancer and influenza vaccine development efforts. Dr. Eagle currently serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at Pfizer Inc.
Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney. He was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his training he performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets. He joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management.
In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the world wide lead for development of celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for irinotecan and dalteparin. In 2007, he became head of the oncology therapeutic area global medical group for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.
"We are very pleased to add Dr. Eagle to our team of scientific advisors," stated Anna Gluskin, the Company's President & Chief Executive Officer. "His wealth of experience in oncology and drug development will be invaluable as we work to advance our vaccine technologies at Antigen Express. Additionally, his hands-on experience in strategic alliances and partnerships will provide us with additional guidance as we seek to commercialize these platforms in the future."
Commenting on his decision to join the scientific advisory board of Generex, Dr. Eagle stated: "I am very excited to be a part of the important advancements in cancer vaccine technologies being made at Generex Oncology. I look forward to advising the Company in its future oncology development efforts and helping Generex to navigate this important platform through its remaining trials and on to eventual commercialization."
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Generex Biotechnology (Nasdaq: GNBT) Develops “Holy Grail” for Diabetics
By Justin Kuepper on Thursday, August 5th, 2010
Generex Biotechnology Corporation (Nasdaq: GNBT), is a biotech company focused on drug delivery systems and technologies, similar to companies like MannKind Corporation (Nasdaq: MNKD), and is also fighting cancer alongside companies like Dendreon Corporation (Nasdaq: DNDN), offers investors both the “holy grail” for insulin shots and a potentially blockbuster cancer treatment in one stock.
Generex Biotechnology Corporation (Nasdaq: GNBT) is a biotech company focused on developing drug delivery systems and promising new cancer treatments. Its flagship product, Generex Oral-lyn is an orally taken insulin spray that is used in place of insulin shots for diabetics. Meanwhile, the firm also has several cancer indications under development that utilize a patient’s own immune system.
Huge Market Using Painful Legacy Technologies
Diabetes is a massive problem in the United States, where it affects approximately 8% of the population, or 23.6 million people. The disease continues to be the seventh leading cause of death as well, with more than 70,000 death certificates listing it as the underlying cause of death in 2006 alone. Meanwhile, diabetes also causes a number of other issues, ranging from blindness to amputation.
The cost of the disease is also massive at over $170 billion in the U.S. alone in 2007. Moreover, an additional $58 billion in indirect costs also had an effect, including disability, work loss, premature mortality and other costs. Despite these horrible statistics, the problem continues to grow with few solutions on the market to even make life more comfortable. (Source: American Diabetes Association)
Diabetics are often forced to take insulin shots to deal with their disease, which can be a painful affair, since they are injections. As a result, many children and adults fail to take these life-saving shots because of the pain and inconvenience, which exacerbates the dangerous health implications and costs. The “holy grail” has always been an injection-free solution that doesn’t have to be stored in the cold.
Generex Offers the Ideal Solution for Diabetics Taking Insulin
Generex offers an oral insulin spray, called Generex Oral-lyn ™, which works similar to an asthma device for diabetics. Unlike injections that take more than 30 minutes to get into the blood stream, the oral spray is nearly instantaneously absorbed to work more quickly. Moreover, the spray does not have to be refrigerated, which makes it far more accessible to the general population.
Currently, Generex Oral-lyn is undergoing global Phase III clinical trials in the U.S., Canada, Russia, Ukraine, Romania and Bulgaria. Safety and efficacy shouldn’t be an issue as the trials wrap up given that the drug has been available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and has been approved in India, Lebanon and Algeria..
Generex Oral-lyn ™, expected for insurance reimbursement approval, could significantly improve its prospects of gaining widespread attention. Today, approximately 23 to 25 million patients use insulin and spend more than $100 million per year on the drug. Of this market, Generex could capture upwards of $60 million per year in the U.S. alone.
The Other Side of the Business: Immunotherapy
Generex is also developing another immunotherapy platform, which can be researched on http://www.antigenexpress.com /. These proprietary vaccine formulations for large, unmet medical needs were designed to combat various types of cancer. These vaccines work by facilitating immune responses that stimulate T helper (Th) cells, which can both enhance and suppress the immune system. These cells have shown a robust and long lasting response against cancer cells, as well as other diseases.
The company’s most advanced drug in this segment, AE37, has been shown to be safe, well tolerated and efficacious in a Phase I clinical trial. Currently, the drug is undergoing Phase II trials designed to examine efficacy in breast cancer patients, while the company is also preparing a Phase I study in prostate cancer at the same time. Finally, the same drug can be used to combat H5N1 and H1N1 flues as well.
Now is the Time to Take Action
Investors interested in a growth stock with numerous near-term catalysts may want to check out Generex Biotechnology Corporation (Nasdaq: GNBT). With a Phase III oral insulin spray that’s already being used in other countries and a promising Phase II cancer treatment platform, this company could begin to make rapid headway in two huge markets.
Moreover, since these trials are coming to an end, investors can expect the company to seek out a commercialization partner to begin providing milestone payments and royalty payments down the road. Combined, this income should generate significant shareholder value, if successfully developed!
http://biotechstocktrader.com/generex-b ... etics-023/
By Justin Kuepper on Thursday, August 5th, 2010
Generex Biotechnology Corporation (Nasdaq: GNBT), is a biotech company focused on drug delivery systems and technologies, similar to companies like MannKind Corporation (Nasdaq: MNKD), and is also fighting cancer alongside companies like Dendreon Corporation (Nasdaq: DNDN), offers investors both the “holy grail” for insulin shots and a potentially blockbuster cancer treatment in one stock.
Generex Biotechnology Corporation (Nasdaq: GNBT) is a biotech company focused on developing drug delivery systems and promising new cancer treatments. Its flagship product, Generex Oral-lyn is an orally taken insulin spray that is used in place of insulin shots for diabetics. Meanwhile, the firm also has several cancer indications under development that utilize a patient’s own immune system.
Huge Market Using Painful Legacy Technologies
Diabetes is a massive problem in the United States, where it affects approximately 8% of the population, or 23.6 million people. The disease continues to be the seventh leading cause of death as well, with more than 70,000 death certificates listing it as the underlying cause of death in 2006 alone. Meanwhile, diabetes also causes a number of other issues, ranging from blindness to amputation.
The cost of the disease is also massive at over $170 billion in the U.S. alone in 2007. Moreover, an additional $58 billion in indirect costs also had an effect, including disability, work loss, premature mortality and other costs. Despite these horrible statistics, the problem continues to grow with few solutions on the market to even make life more comfortable. (Source: American Diabetes Association)
Diabetics are often forced to take insulin shots to deal with their disease, which can be a painful affair, since they are injections. As a result, many children and adults fail to take these life-saving shots because of the pain and inconvenience, which exacerbates the dangerous health implications and costs. The “holy grail” has always been an injection-free solution that doesn’t have to be stored in the cold.
Generex Offers the Ideal Solution for Diabetics Taking Insulin
Generex offers an oral insulin spray, called Generex Oral-lyn ™, which works similar to an asthma device for diabetics. Unlike injections that take more than 30 minutes to get into the blood stream, the oral spray is nearly instantaneously absorbed to work more quickly. Moreover, the spray does not have to be refrigerated, which makes it far more accessible to the general population.
Currently, Generex Oral-lyn is undergoing global Phase III clinical trials in the U.S., Canada, Russia, Ukraine, Romania and Bulgaria. Safety and efficacy shouldn’t be an issue as the trials wrap up given that the drug has been available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and has been approved in India, Lebanon and Algeria..
Generex Oral-lyn ™, expected for insurance reimbursement approval, could significantly improve its prospects of gaining widespread attention. Today, approximately 23 to 25 million patients use insulin and spend more than $100 million per year on the drug. Of this market, Generex could capture upwards of $60 million per year in the U.S. alone.
The Other Side of the Business: Immunotherapy
Generex is also developing another immunotherapy platform, which can be researched on http://www.antigenexpress.com /. These proprietary vaccine formulations for large, unmet medical needs were designed to combat various types of cancer. These vaccines work by facilitating immune responses that stimulate T helper (Th) cells, which can both enhance and suppress the immune system. These cells have shown a robust and long lasting response against cancer cells, as well as other diseases.
The company’s most advanced drug in this segment, AE37, has been shown to be safe, well tolerated and efficacious in a Phase I clinical trial. Currently, the drug is undergoing Phase II trials designed to examine efficacy in breast cancer patients, while the company is also preparing a Phase I study in prostate cancer at the same time. Finally, the same drug can be used to combat H5N1 and H1N1 flues as well.
Now is the Time to Take Action
Investors interested in a growth stock with numerous near-term catalysts may want to check out Generex Biotechnology Corporation (Nasdaq: GNBT). With a Phase III oral insulin spray that’s already being used in other countries and a promising Phase II cancer treatment platform, this company could begin to make rapid headway in two huge markets.
Moreover, since these trials are coming to an end, investors can expect the company to seek out a commercialization partner to begin providing milestone payments and royalty payments down the road. Combined, this income should generate significant shareholder value, if successfully developed!
http://biotechstocktrader.com/generex-b ... etics-023/
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Quem está ligado:
Utilizadores a ver este Fórum: Google Adsense [Bot] e 203 visitantes